Supplementary Table. Percentage of patients with a measurable change in headache severity among patients with <30% reduction in headache-day frequency.

| Patients with severity response (≥1-grade improvement from baseline in severity based on patient diary) | OnabotulinumtoxinA / OnabotulinumtoxinA | Placebo / OnabotulinumtoxinA | P-value |
|---|---|---|---|
| n=194 | n=261 | |
| Week 24 | 24.2% | 13.8% | 0.004 |
| Week 56 | 54.1% | 57.9% | 0.428 |
Supplementary Figure 1. Change from baseline in the number of severe headache days per 28-day period, among patients with <30% reduction in headache-day frequency.

*P<0.001, †P<0.05.
Supplementary Figure 2. Percentage of severe headache days, pooled across patients with <30% reduction in headache-day frequency.
*P<0.001, †P<0.05.